Table 2.

Demographic and clinical manifestations of patients with juvenile idiopathic arthritis

Age at the study (years), med (min–max)	12.5 (2–20)
Gender, n (%)
Female	124 (51)
Male	119 (49)
Disease duration (mo), med (min–max)	42 (4–221)
JADAS-27 at last visit (mean ± SD) (range)	2.2 ± 4.9 (0–20)
Nonbiologic DMARDs Type, n (%); Duration (mo), med (min–max)
Methotrexate	226 (93)	18 (2–114)
Leflunomide	41 (16.9)	12 (5–60)
Sulfasalazine	53 (21.8)	6 (1–24)
Hydroxychloroquine	3 (1.2)	4 (3–4)
Biologic DMARDs Type, n (%); Duration (mo), med (min–max)
Etanercept	97 (39.9)	14 (2–60)
Adalimumab	54 (22.2)	12 (2–36)
Infliximab	4 (1.6)	11 (3–24)
Tocilizumab	35 (14.4)	14 (3–76)
Anakinra	12 (4.9)	4 (1–8)
Canakinumab	8 (3.3)	24 (6–36)
Abatacept	4 (1.6)	16 (9–18)
JAK inhibitors Type, n (%); Duration (mo), med (min–max)
Tofacitinib	1 (0.4)	3

JADAS Juvenile Arthritis Disease Activity Score-27, DMARDs Disease-modifying antirheumatic drugs, JAK inhibitors Janus kinase enzyme inhibitors